Bone Cancer Drugs Market | Leading Segments, Trends, Drivers and Challenges

Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Merck and Co. Inc. are among the key vendors discussed in the market research report

The bone cancer drugs market is expected to grow by $ 996.69 million, accelerating at a CAGR of almost 5.46% during the forecast period. Technavio’s research report traces the growth trajectory of the market and provides a detailed analysis of the prevalent market forces, trends, and drivers which are likely to impact the market in focus.

For a snapshot of our exhaustive research analysis and insights:  Request for Our Free Sample Report

Bone Cancer Drugs Market: Market Segments and Growth Forecasts

This research report will provide insights into the current market share of each segment along with growth projections for the next five years. 

• Market is segmented Market Landscape (Osteosarcoma, Ewing's sarcoma, Chondrosarcoma, and Other bone cancers) and Geography (North America, Europe, Asia, and ROW). 
• 51% of the market growth will originate from North America during the forecast period. This report provides an accurate prediction of the contribution of all the geographic segments to the growth of the Bone Cancer Drugs Market size. 

Bone Cancer Drugs Market: Trends, Drivers, Challenges
The report also offers a detailed impact analysis of various trends, drivers, and challenges that are likely to influence the market growth during the forecast period. These insights will equip clients to design a growth strategy for their business and area of operations.

• Rising prevalence of osteosarcoma in younger patients will increase the need for bone cancer drugs and targeted therapies such as XGEVA. Osteosarcoma affects the bones around the knee and creates complications in terms of mobility in patients.
• The emergence of targeted therapies for the treatment of bone cancer will drive bone cancer drugs market growth. Targeted therapies such as PD-1, PD-L1, and SRC family kinase inhibitors are being approved for the treatment of various types of bone cancers. 
• Preference for surgery over treatment throught drugs is a hurdle that needs to be crossed on the path to further market growth.

Bone Cancer Drugs Market: Vendor Analysis

The market is concentrated. The growth of the players depends on several factors such as market conditions, government support, and industry development. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions. Amgen Inc., Baxter International Inc., Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments.

For more insights into this market: Download a Free Sample Report. Our custom reports provide market insights at the global and regional level along with a pipeline analysis of new product launches. It also provides a peek into the latest R&D along with impact analysis of government regulations.

Browse through some of other related market research reports for more insights:

• Brain Tumor Therapeutics Market: Global brain tumor therapeutics market is likely to post an incremental growth of $ 1231.74 million, accelerating at a CAGR of 9.67% during the forecast period.
• Medical Imaging Market: The medical imaging market is expected to grow by $ 13.49 billion, accelerating at a CAGR of almost 6.71% during the forecast period.
• Contract Development and Manufacturing Organization (CDMO) Outsourcing Market: The CDMO outsourcing market is expected to grow by $ 64.44 billion, accelerating at a CAGR of almost 11.12% during the forecast period.
• Biologics CDMO Market: The biologics CDMO market is expected to grow by $ 8.65 bn, accelerating at a CAGR of almost 12.20% during the forecast period.
• Cancer Registry Software Market: Global cancer registry software market is likely to post an incremental growth of $ 54.20 million, accelerating at a CAGR of 11.19% during the forecast period.

The report provides insights into the following FAQs:

1. What is the market CAGR?
   The market will accelerate at a CAGR of over 5.46%.
    
2. What is the incremental growth of the market?
   The market is expected to grow by $ 996.69 mn through 2021-2025.
    
3. What is a key factor driving this market?
   Strong prevalence of osteosarcoma in younger patients will drive market growth over the forecast period.
    
4. What are the key regions covered in this market research report?
   North America, Europe, Asia, and ROW are the key regions featured in this research report.
    
5. Which is the leading geographic region for this market:
   51% growth will originate from North America
    
6. Who are the leading market vendors?
   The leading vendors in this market are Amgen Inc., Baxter International Inc., Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
    
7. What are the market segments covered in this report?
   The market is segmented by Market Landscape (Osteosarcoma, Ewing's sarcoma, Chondrosarcoma, and Other bone cancers) and Geography (North America, Europe, Asia, and ROW)

The Global Bone Cancer Drugs Market 2020-2024, is expected to grow by USD 911.76 million, accelerating at a CAGR of over 6% during the forecast period. Although the healthcare industry is expected to witness positive growth as a result of COVID-19, the impact of the pandemic on the market in focus is expected to remain NEUTRAL. Technavio evaluates the market with a detailed investigation into the market forces, emerging trends, and growth drivers. It also provides competitive benchmarking to equip clients with actionable insights that will help them navigate through the current market scenario. Preview our latest report

"The emergence of targeted therapies for the treatment of bone cancer will also drive market growth. Targeted therapies such as PD-1, PD-L1, and SRC family kinase inhibitors are being approved for the treatment of various types of bone cancers", says senior research analyst for the Health Care Industry at Technavio.

Bone Cancer Drugs Market: Type Segment Highlights

• Segmentation by Indication: Osteosarcoma, Ewing's sarcoma, chondrosarcoma, and Other bone cancers
• Osteosarcoma segment dominated the market in recent years owing to factors such as increasing awareness about osteosarcoma, which will fuel market growth.
• Growth in the osteosarcoma market segment will be faster than the growth of the market in the chondrosarcoma segment during the forecast period.

Bone Cancer Drugs Market: Competitive Analysis

• The Bone Cancer Drugs Market is concentrated due to the presence of few vendors.
• Market vendors are focused on offering novel therapies and chemotherapy drugs approved for the treatment of various indications, including bone cancer.
• Amgen Inc., Baxter International Inc., Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, and Pfizer Inc. are some of the major market participants.Although the growing trend of osteosarcoma in younger patients will offer immense growth opportunities, the adverse side effects will challenge the growth of the market participants. 

Technavio provides custom research reports with detailed insights on the impact of COVID-19 with respect to the industry, region, and supply chain operations. This customized report will help clients keep up with new product launches in direct & indirect COVID-19 related markets. It will also provide insights on upcoming developments along with pipeline analysis of vendor operations and the impact of government regulations. Download a Free Sample Report